What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025BloodOpen Access

Efficacy, quality of life, and safety of non-clotting factor prophylaxis in Hemophilia A and b: A meta-analysis across inhibitor status

View Full Paper

Ask AI

Bookmark

Non-clotting factor prophylaxis significantly reduces annualized bleeding rates in hemophilia A and B patients, improving quality of life and treatment outcomes.
Meta-analysis of 7 randomized controlled trials showed prophylaxis lowered rates of spontaneous and joint bleeds compared to on-demand therapy.
Study participants included 531 patients with congenital hemophilia across various age groups, indicating broad applicability of findings.
While adverse events were noted, non-clotting factor prophylaxis did not increase the risk of serious adverse events compared to traditional therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Meta-analysis demonstrates improved quality of life and reduced bleeding in hemophilia A and B patients with non-clotting factor prophylaxis, highlighting benefits over on-demand therapy.

Cite This Study

Memon et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbde https://doi.org/10.1182/blood-2025-6628

View Full Paper

Ask AI

Bookmark

Implication

Meta-analysis demonstrates improved quality of life and reduced bleeding in hemophilia A and B patients with non-clotting factor prophylaxis, highlighting benefits over on-demand therapy.

Efficacy, quality of life, and safety of non-clotting factor prophylaxis in Hemophilia A and b: A meta-analysis across inhibitor status

Key Points

Discussion

Implication

Cite This Study

Efficacy, quality of life, and safety of non-clotting factor prophylaxis in Hemophilia A and b: A meta-analysis across inhibitor status

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider